Author

E. Davidson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 9 Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Organism:human· 11 Research Focus:host-pathogen & immune response· 8 Assay:proteomics· 6 Research Focus:cell type annotation· 5 Research Focus:drug response / drug discovery· 4 Assay:scRNA-seq· 3 Approach:statistical model· 3

Frequent Co-Authors

B. J. Doranz· 7 shared J. E. Crowe· 7 shared R. H. Carnahan· 6 shared B. Doranz· 5 shared P. Gilchuk· 5 shared E. Binshtein· 4 shared N. Suryadevara· 4 shared A. Bukreyev· 3 shared

Activity by Year

2019-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

B. J. Doranz

Mutual co-authors in cluster

Author profile →

13 papers

Recent·Most cited

Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses

J. Lubow, L. M. Levoir, D. K. Ralph, L. Belmont, M. Contreras, C. H. Cartwright-Acar, C. Kikawa, S. Kannan, E. Davidson, B. J. Doranz, V. Duran, D. E. Sanchez, A. M. Sanz, F. Rosso, S. Einav, , L. Goo

The paper uses single-cell transcriptomics to identify new broadly neutralizing antibodies against flaviviruses, including an IgA1 isotype with unique neutralizing properties.

PLOS Pathogens · Oct 9, 2023Peer-reviewedMicrobiology

Broadly neutralizing antibodies target the coronavirus fusion peptide

C. Dacon, C. Tucker, L. Peng, C.-C. D. Lee, T.-H. Lin, M. Yuan, Y. Cong, L. Wang, L. Purser, J. K. Williams, C.-W. Pyo, I. Kosik, Z. Hu, M. Zhao, D. Mohan, , J. Tan

The paper identifies six monoclonal antibodies that broadly neutralize coronaviruses by targeting the conserved fusion peptide.

bioRxiv · Apr 11, 2022Immunology

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, , J. E. Crowe

The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.

bioRxiv · Jan 12, 2022 · PreprintImmunology

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

N. Suryadevara, A. Shiakolas, L. VanBlargan, E. Binshtein, R. Chen, J. B. Case, K. Kramer, E. Armstrong, L. Myers, A. Trivette, C. Gainza, R. Nargi, C. Selverian, E. Davidson, B. Doranz, , J. E. Crowe

The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.

bioRxiv · Jan 12, 2022Immunology

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition

K. J. Kramer, N. V. Johnson, A. R. Shiakolas, N. Suryadevara, S. Periasamy, N. Raju, J. K. Williams, D. Wrapp, S. J. Zost, C. M. Holt, C.-L. Hsieh, R. E. Sutton, A. Paulo, E. Davidson, B. J. Doranz, , I. S. Georgiev

This study identifies a potent SARS-CoV-2 antibody, 54042-4, that neutralizes variants of concern and has a unique epitope and genetic structure.

bioRxiv · May 16, 2021Immunology

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

E. C. Chen, P. Gilchuk, S. J. Zost, N. Suryadevara, E. S. Winkler, C. R. Cabel, E. Binshtein, R. E. Sutton, J. L. Rodriguez, S. Day, L. Myers, A. Trivette, J. K. Williams, E. Davidson, S. Li, , J. E. Crowe

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

bioRxiv · May 2, 2021Immunology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein

N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe

The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.

bioRxiv · Jan 19, 2021Immunology

A novel antigenic site spanning domains I and III of the Zika virus envelope glycoprotein is the target of strongly neutralizing human monoclonal antibodies

S. Graham, H. A. Tu, B. D. McElvany, N. R. Graham, A. Grinyo, E. Davidson, B. J. Doranz, S. A. Diehl, A. M. de Silva, A. J. Markmann

This study identifies a novel antigenic site on the Zika virus envelope glycoprotein targeted by a strongly neutralizing human monoclonal antibody, providing insights for vaccine design.

bioRxiv · Dec 21, 2020Immunology

Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications

J. C. Whitbeck, A. Thomas, K. Kadash-Edmondson, A. Grinyo i Escuer, C. Cheng, G. C. Liao, F. W. Holtsberg, M. J. Aman, G. Simmons, E. Davidson, B. J. Doranz

This study validates ZIKV reporter virus particles (RVPs) as stable, reproducible, and antigenically identical to live virus for large-scale neutralization assays and vaccine development.

PLOS Neglected Tropical Diseases · Nov 18, 2020Peer-reviewedMicrobiology

Convergence of a common solution to broad ebolavirus neutralization by glycan cap directed human antibodies

C. D. Murin, P. Gilchuk, P. Ilinykh, K. Huang, N. Kuzmina, X. Shen, J. F. Brunh, A. L. Brunh, E. Davidson, B. Doranz, L. E. Williamson, J. Copps, T. Alkutkar, A. I. Flyak, A. Bukreyev, , A. B. Ward

The paper presents cryo-EM structures of glycan cap antibodies that neutralize ebolavirus by targeting a conserved MLD-anchor site, revealing common features among broadly neutralizing antibodies.

bioRxiv · Oct 14, 2020Immunology

An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency

T. Kotaki, T. Kurosu, A. Grinyo, E. Davidson, S. Churrotin, T. Okabayashi, O. Puiprom, K. C. Mulyatno, T. H. Sucipto, B. Doranz, K.-i. Ono, S. Soegijanto, M. Kameoka

This study identifies an affinity-matured human monoclonal antibody, 3G9, targeting the fusion loop epitope of dengue virus that shows strong neutralization and reduced antibody-dependent enhancement in vivo.

bioRxiv · Oct 3, 2020Microbiology

Integrated technology platform for accelerated discovery of antiviral antibody therapeutics

P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. S. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Dunellin, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. Doranz, , R. H. Carnahan

This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.

bioRxiv · May 12, 2020Immunology

Functional characterization and lineage analysis of broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics

N. D. Durham, A. Agrawal, E. Waltari, D. Croote, F. Zanini, M. Fouch, E. Davidson, O. Smith, E. Carabajal, J. E. Pak, B. J. Doranz, M. Robinson, A. M. Sanz, L. L. Albornoz, F. Rosso, , L. Goo

The paper identifies two broadly neutralizing antibodies against dengue virus through single B cell transcriptomics and characterizes their epitopes and evolutionary pathways.

bioRxiv · Oct 2, 2019Microbiology